Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Phebe De Nocker"'
Autor:
Leila Karimi, Lies Lahousse, Phebe De Nocker, Bruno H. Stricker, Guy G. Brusselle, Katia M.C. Verhamme
Publikováno v:
ERJ Open Research, Vol 7, Iss 2 (2021)
Observational studies report a reduction of COPD exacerbations in patients treated with β-blockers. In contrast, the Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (BLOCK COPD) randomised controlled
Externí odkaz:
https://doaj.org/article/7536fbbdd485431091a99b9433b35f1d
Autor:
Bruno H. Stricker, Lies Lahousse, Katia M.C. Verhamme, Leila Karimi, Phebe De Nocker, Guy Brusselle
Publikováno v:
ERJ OPEN RESEARCH
ERJ Open Research, Vol 7, Iss 2 (2021)
ERJ Open Research
article-version (VoR) Version of Record
ERJ Open Research, Vol 7, Iss 2 (2021)
ERJ Open Research
article-version (VoR) Version of Record
Observational studies report a reduction of COPD exacerbations in patients treated with β-blockers. In contrast, the Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (BLOCK COPD) randomised controlled
Autor:
Caroline Emilie, Phebe de Nocker, Nadia Saïdani, Mark Gilchrist, R. Andrew Seaton, Sanjay Patel, Guillaume Beraud, Diamantis Kofteridis, Jeroen Schouten, Nathalie Thilly, Marvin Berrevoets, Marlies Hulscher, Franky Buyle, Céline Pulcini
Publikováno v:
International Journal of Antimicrobial Agents, 59
International Journal of Antimicrobial Agents, 59, 4
International Journal of Antimicrobial Agents, 59, 4
Item does not contain fulltext Delivery of parenteral antimicrobials in non-inpatient settings (DPANS) may be through a dedicated outpatient parenteral antimicrobial therapy (OPAT) service, co-ordinated by hospital- or community-based specialised tea
The effect of the indicated use of ß-blockers on the risk of COPD exacerbations: the Rotterdam Study
Autor:
Leila Karimi, Bruno H. Stricker, Guy Brusselle, Phebe De Nocker, Lies Lahousse, Katia M.C. Verhamme
Publikováno v:
Airway pharmacology and treatment.
Background: While observational studies suggest a reduced risk of exacerbation in COPD patients treated with β-blockers (BB), there is reluctance to prescribe BB in patients with cardiovascular disease (CVD) and concomitant COPD. Recently, the BLOCK
Publikováno v:
ERS Lung Science Conference 2016.
Autor:
Guy Brusselle, Katia M.C. Verhamme, Phebe De Nocker, Lies Lahousse, Bruno H. Stricker, A. Hofman
Background While β-blockers are known to be protective in patients with cardiovascular disease, retrospective studies have suggested that β-blockers also have beneficial effects in patients with chronic obstructive pulmonary disease (COPD). To inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5a1c73f068c9635a8457d4d69af97b
https://europepmc.org/articles/PMC4958773/
https://europepmc.org/articles/PMC4958773/